Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Long-Term Opioid Study: FDA AdCom Says Proposed PMR Design Is Feasible, But Unlikely To Provide Significant Info; Is There A Safe Next Step?

April 24, 2023

MedPAC Eyeing PBMs As Next Frontier In Part D Oversight; Finance Committee “Framework” Focuses On “De-Linking” PBM Payment From Drug Prices

April 21, 2023

Prevision Policy Clips | Novavax COVID Vaccine Update Process: “Technical Challenges” Will Be Focus Of FDA Workshop April 27

April 21, 2023

Prevision Policy Clips | Cell/Gene Therapy Clinical Holds: FDA Commissioner Califf Acknowledges “Issues”

April 20, 2023

COVID Vaccine “Simplification”: Original Formula No Longer Authorized; June AdCom Will Select Strain Likely To Launch Commercially – Will Single Booster Boost Uptake?

April 19, 2023

Innoviva/Entasis SUL-DUR AdCom Goes Smoothly; FDA Office Of Infectious Diseases Shows Finesse In Moving “Streamlined” Reviews Forward

April 19, 2023

Prevision Policy Clips | FDA External Affairs Interim Head Will Be Heidi Rebello

April 19, 2023

Prevision Policy Clips | FDA Moves To Bivalent-Only COVID Vaccine Model, Authorizes Second Bivalent Booster In Some Populations

April 18, 2023

Long Wait For Long-Term Opioid Trial: FDA Seeks Committee Support For Novel Withdrawal Design To Fulfill Decade-Old Post-Marking Requirement

April 17, 2023

Otsuka/Lundbeck’s Rexulti Clears FDA Committee For Alzheimer’s Agitation: Efficacy Is Small But Clear; Mortality Risk Is “Consistent” With Class Effect

April 17, 2023

Prevision Policy Clips | COVID Vaccine “Anticipated Regulatory Changes” Prompt ACIP Meeting On Short Notice

April 17, 2023

FDA Tries Again On Opioid Relabeling: Updated Indication, New Warning About Hyperalgesia Ordered Ahead of April 19 Advisory Committee Discussion Of Delayed Post-Marketing OIH Trial

April 14, 2023

Innoviva/Entasis SUL-DUR Advisory Committee Appears Set To Showcase “Streamlined” FDA Approach To Anti-Infective Development For Unmet Needs

April 14, 2023

Prevision Policy Clips | FDA Rare Disease Endpoint Advancement (RDEA) Pilot: June 7-8 Workshop

April 14, 2023

New Technology Add-On Payments: CMS Proposes Earlier Deadline For FDA Approval To Qualify In Future Years; 19 Drugs Under Consideration For NTAP Status In FY 2024

April 13, 2023

Part B Drug Pricing Reforms Endorsed By MedPAC: Is There Appetite For More Changes Amid IRA Implementation?

April 13, 2023

Prevision Policy Clips | Pragmatica-Lung Phase 3 Advanced NSCLC Survival Trial With Cyramza/Keytruda

April 13, 2023

FDA Guidance “Snapshots” Pilot Explained: CDER Describes Purpose Of Initiative, Patient-Directed Explanations Up Next

April 12, 2023

Otsuka/Lundbeck’s Rexulti In Alzheimer’s Agitation Benefit/Risk To Be Debated By FDA Advisory Committee: Can An Appropriate Population Be Identified?

April 12, 2023

Shortage Notification Guidance Updated: COVID-Era Message To Manufacturers To Err On The Side Of Informing FDA Will Continue Post-Pandemic

April 12, 2023

Prevision Policy Clips | Quantity Reporting: FDA Finalizes Exemption For Single-Use Gene/Cell Therapy Lots

April 12, 2023

Prevision Policy Clips | CMS Projects Novel Anti-Infectives Could Net $213 Mil. In Add-On Payments For FY 2024

April 11, 2023

Prevision Policy Clips | Sarepta DMD Gene Therapy Advisory Committee Set For May 12

April 10, 2023

Prevision Policy Clips | Makena And Generics Formally Withdrawn Immediately, FDA Commissioner Califf And Chief Scientist Bumpus

April 7, 2023

Accelerated Approval Planning For Rare Diseases: FDA “ARC” Initiative Aims To Encourage Early Discussions – Even At Pre-IND Phase

April 7, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy